Clinical Trial Details

A Muticenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of Asapiprant in Hospitalized Patients Over Sixty Years of Age with COVID-19 [BioAge] [Protocol # BGE-175-201]

Detailed Description:

This is a randomized, placebo-controlled, parallel-group, multicenter, double-blind study of BGE-175 administered PO or NG in participants ≥ 50 years of age and hospitalized with documented COVID-19 who are not yet in respiratory failure.

Sponsor Study Website

Learn More

Principal Investigator(s)


BioAge Labs, Inc.


Carolina Garavito at 203-358-8879 or [email protected]


Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.